SpringerLink
Log in

CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Patients with recurrent or refractory Hodgkin's and non-Hodgkin's lymphoma are increasingly being treated with high-dose therapy and hematopoietic cell transplantation. As minimal disease status at the time of transplant has been a repeatedly proven significant prognostic factor for long-term survival, effective initial cytoreduction is an important step in the process. Modern chemotherapy programs for Hodgkin's lymphoma include virtually all active agents and little is left for effective salvage. Mitoxantrone is an active agent in lymphoma that is not generally used in first-line treatment. The aim of this study was to determine toxicity and response rate to CN3OP (fractionated mitoxantrone 6 mg/m2 on days 1,2 and 3, combined with standard dose cyclophosphamide, vincristine, and prednisone) in 44 patients with relapsed or refractory lymphoma., Most of patients had advanced disease and one or more extranodal sites at relapse. Median response duration to immediate past therapy was four months, and one third of patients had not responded to prior treatment. A median of 4 cycles of CN3OP were given per patient for a total of 173 cycles. Grade III–IV neutropenia occured in 53% of cycles, Grade I–III mucositis in 24%, and Grade I–III infection in 17% of cycles. of 34 evaluable patients with Hodgkin's lymphoma 12 (35%) achieved complete remission (CR) and 15 (44%) partial remission (PR) for an overall response rate of 79%. Two of five evaluable non-Hodgkin's lymphoma patients responded with PR. Median overall survival and event free survival in the entire group was 29 months and 11 months respectively. At this time 16 patients have died; 12 of lymphoma, two of unknown cause and two of other causes. Complete response to CN3OP correlated with survival. CN3OP is an effective and safe regimen for cytoreduction in Hodgkin's lymphoma patients pretreated with doxorubicin/alkylator/etoposide-containing primary therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chopra Ret al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-centre eight-year study of 155 patients.Blood 1993;81: 1137–1145.

    Article  CAS  PubMed  Google Scholar 

  2. Horning Set al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.Blood 1997;89: 801–813.

    Article  CAS  PubMed  Google Scholar 

  3. Lancet JEet al. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.Bone Marrow Transplant 1998;22: 265–271.

    Article  CAS  PubMed  Google Scholar 

  4. Sweetenham JWet al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induuction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation.J Clin Oncol 1999;17: 3101–3109.

    Article  CAS  PubMed  Google Scholar 

  5. Yuen ARet al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease.Blood 1997;89: 814–822.

    Article  CAS  PubMed  Google Scholar 

  6. Fisher RI, De Vita VT, Hubbard SP, Simon R, Young RC. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.Ann Intern Med 1979;90: 761–763.

    Article  CAS  PubMed  Google Scholar 

  7. Viviani Set al. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission.Ann Oncol 1990;1: 123–127.

    Article  CAS  PubMed  Google Scholar 

  8. Aisenberg AC. Problems in Hodgkin's Disease Management.Blood 1999;93: 761–779.

    Article  CAS  PubMed  Google Scholar 

  9. Canellos GPet al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.New Engl J Med 1992;327: 1478–84.

    Article  CAS  PubMed  Google Scholar 

  10. Rapoport APet al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome.J Clin Oncol 1993;11: 2351–61.

    Article  CAS  PubMed  Google Scholar 

  11. Velazquez WSet al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP).Blood 1988;71: 117–122.

    Article  Google Scholar 

  12. Rodriguez MA, Cabanillas FC, Velazquez WS. Results of a salvage treatment program for relapsing lymphoma: MESNA/ifosfamide, novantrone, and etoposide (MINE), consolidated with etoposide, solumedrol, high dose arabinoside and cisplatinum (ESHAP).J Clin Oncol 1995;13: 1734–1741.

    Article  CAS  PubMed  Google Scholar 

  13. Wilson WHet al. EPOCH Chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.J Clin Oncol 1993;11: 1573–1582.

    Article  CAS  PubMed  Google Scholar 

  14. Wilson WH, Bryant G, Wittes R, Steinberg S, Chabner B. EPOCH chemotherapy is effective in relapsed and refractory Hodgkin's disease.Proc ASCO 1995;14: Abstr 1224.

    Google Scholar 

  15. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicn, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for schedule-dependent effect favoring infusional administration of chemotherapy.J Clin Oncol 1993;11: 1071–1079.

    Article  CAS  PubMed  Google Scholar 

  16. Santoro Aet al. CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin's disease.Semin Oncol 1986;13 (Suppl 1): 23–26.

    CAS  PubMed  Google Scholar 

  17. Pfreundschuh MG, Schoppe WD, Fuchs KH. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastin, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin's Study Group.Cancer Treat Rep 1987;71: 1203–1207.

    CAS  PubMed  Google Scholar 

  18. Richards MAet al. EVA treatment for recurrent or unresponsive Hodgkin's disease.Cancer Chemother Pharmacol 1986;18: 51.

    Article  CAS  PubMed  Google Scholar 

  19. Radford JA, Crowther D. Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: results of a pilot study in 20 patients.Ann Oncol 1991;2: 505–509.

    Article  CAS  PubMed  Google Scholar 

  20. Smith IE. Mitoxantrone: A review of experimental and early clinical studies.Cancer Treat Rev 1983;10: 103–115.

    Article  CAS  PubMed  Google Scholar 

  21. Gams RA, Steinberg J, Posner L. Mitoxantrone in malignant lymphoma.Semin Oncol 1984;11: 47–49.

    CAS  PubMed  Google Scholar 

  22. Crossley RJ. Clinical safety and tolerance of mitoxantrone.Sem Oncol 1984;11 (Suppl 1): 54–58.

    CAS  Google Scholar 

  23. Silver RTet al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.J Clin Oncol 1991;9: 754–761.

    Article  CAS  PubMed  Google Scholar 

  24. Bajetta Eet al. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas.Am J Clin Oncol 1988;11: 100–103.

    Article  CAS  PubMed  Google Scholar 

  25. Ruit JBet al. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.Semin Oncol 1990;17: 24–27.

    CAS  PubMed  Google Scholar 

  26. Tirelli Uet al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.J Clin Oncol 1992;10: 228–236.

    Article  CAS  PubMed  Google Scholar 

  27. Wiernik PHet al. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.The Cancer Journal from Scientific American 1998;4: 254–260.

    CAS  PubMed  Google Scholar 

  28. Philip Tet al. Autologous bone marrow transplantation as compared with, salvage chemotherapy in relapses, of chemotherapy-sensitive non-Hodgkin's lymphoma.New Engl J Med 1995;333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  29. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation.J Am stat Assoc 1958;53: 457–481.

    Article  Google Scholar 

  30. Cox DR. Regression models and life tables.J R Stat Soc B 1972;34: 187–220.

    Google Scholar 

  31. Walewski J, Krzyzanowska JB. Phase II study of CN3OP-cyclophosphamide, mitoxantrone day 1, 2, and 3, vincristin, and prednisone: effective and safe reinduction chemotherapy for refractory lymphoma.Blood 1998;92 (Suppl 1): abstract 4038.

    Google Scholar 

  32. Rodriguez Jet al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease.Blood 1999;11: 3632–3636.

    Article  Google Scholar 

  33. Ribrag Vet al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.Bone Marrow Transplant 1998;21: 969–974.

    Article  CAS  PubMed  Google Scholar 

  34. Brusamolino Eet al. Results of CAV regimen (CCMU, melphalan, and VP16) as third line salvage regimen for Hodgkin's disease.Ann Oncol 1994;5: 427.

    Article  CAS  PubMed  Google Scholar 

  35. Diehl Vet al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease.Ann Oncol 1997;8: 143–148.

    Article  CAS  PubMed  Google Scholar 

  36. Hancock BWet al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial.J Clin Oncol 1992;10: 1252–58.

    Article  CAS  PubMed  Google Scholar 

  37. Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An updata.Ann Oncol 1996;7(Suppl 4): S105 abstract.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoproliferative Diseases, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 5 W.K. Roentgen Street, 02-781, Warszawa, Poland

    J Walewski, JB Krzyżanowska, E Kraszewska, E Lampka, J Romejko-Jarosińska, Z Miśkiewicz & J Meder

Authors
  1. J Walewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JB Krzyżanowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Kraszewska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Lampka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Romejko-Jarosińska
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z Miśkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Meder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Walewski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walewski, J., Krzyżanowska, J., Kraszewska, E. et al. CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma. Med Oncol 17, 195–202 (2000). https://doi.org/10.1007/BF02780528

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02780528

Keywords

Search

Navigation